AMCP Partnership Forum: Driving Value and Outcomes in Oncology

作者:Anhorn Rachel; Allmon Tracy Baroni; Borgert Rebecca; Buckley Sean; Carter Harold L; Carter Laurent; Child Berrie C; Chiu Tim; Cox Ryan M; Dimascio Suzette; Drozd Michelle; Grubbs Stephen; Mallender Jaque; Hogan Kevin; Hudspeth Louis; Jacobson Rob; Kapustyan Tatyana; Kissel Edward; Lang James R; Meyer Kellie; Moncuso Donna; Mulvey Therese M; Nguyen Ann; Owens Gary M; Pelletier Corey; Peters Sarah Scarpace; Pherwani Nisha; Rihani Rami; Roth Joshua
来源:Journal of Managed Care & Specialty Pharmacy, 2017, 23(5): 591-597.
DOI:10.18553/jmcp.2017.23.5.591

摘要

Innovation in cancer treatment has provided a wealth of recently available therapeutic agents and a healthy drug pipeline that promises to change the way we approach this disease and the lives of those affected in the years to come. However, the majority of these new agents, many of which are targeted to specific genomic features of various tumors, may challenge the health care system's ability to afford cancer care. This innovation drives the need to focus on the value of the treatments provided to patients with cancer and on methods to optimize the efficiency of the dollars we spend, in addition to the clinical value itself. The Academy of Managed Care Pharmacy (AMCP) convened a Partnership Forum to address how to improve value and outcomes in cancer care. In this multistakeholder forum, several areas were addressed: current methods for assessing the value of oncology products, the need for balancing population management with precision medicine, and the outlook for value-based contracting for oncology medications in managed care settings. Participants recommended ways in which stakeholders can work toward solutions in these areas. The forum brought together stakeholders from health plans, integrated delivery systems, pharmacy benefit managers, clinical practice, biopharmaceutical industry, and laboratory companies. Also participating were representatives from trade and professional associations. During this 1.5-day forum, participants identified current challenges, readiness, and ways to address value and improve outcomes in cancer therapy. Some of the challenges identified include choosing a viable (and practical) outcome target for value-based contracting in oncology, the development and use of value frameworks and clinical pathways, managing cancer diagnostics, utilization of alternative payment systems, moving from a large evidence base to a small clinical trial base in considering targeted treatments, and lack of best practices in value-based payment arrangements. Addressing these challenges could lead to improving cancer treatment.

  • 出版日期2017-5